Abstract 1854P
Background
Impaired perception of time has been associated with many psychiatric and neurological diseases. Time perception has been studied with different validated scales in the literature. However, the length of these scales limits its feasibility. The aim of our study was to evaluate the relationship of “1 minute” time perception with depression and anxiety in cancer patients receiving chemotherapy.
Methods
The cancer patients receiving active systemic therapy were included in the study. Time perception assessment was performed by testing how they perceived the 1-minute period. The patients were asked to guess the length of 1 minute by using a chronometer. Time perception duration (TPD) were recorded. The median 39 seconds was used to categorize patients as fast and slow time perception. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale (HADS).
Results
In the study; 242 patients with a median age of 61 (33-88 years) were evaluated. In the TPD evaluation, the median estimation time was 39s (7-135sec) and 50.4% was found to be rapid time perception (<39sec). Anxiety and depression scores were recorded as high in 12% of the patients. There was no significant correlation between TPD and anxiety (r=0.027, p=0.68) and depression scores (r= 0.017, p= 0.79). TPD was similar between the groups with high and normal anxiety scores (39 vs 39 sec, p= 0.90) and those with short perception patients were similar in both groups (51.7% vs 50.2%, p=0.51). TPD was shorter in those with high depression scores (34 vs 40s, p= 0.37). Those with rapid TDP were more common in these patients, but this did not reach statistical significance (58.6% vs 49.3%, p= 0.22). In the multivariate analysis. Female gender and low income were found to be risk factors for high anxiety scores.
Conclusions
The 1-minute time perception assessment could not be shown to be effective in predicting depression and anxiety scores. In our study, in which the group with high depression/anxiety scores was low, the small sample size may be the reason for the insignificant result. Testing the efficacy of 1 minute time perception in larger groups can provide important data to the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05